Silexion initiates Phase 2/3 SIL204 trial in locally advanced pancreatic cancer at Tel Aviv Sourasky Medical CenterPUBT·1 day ago, 06:35 AMSLXN+15.00%
Silexion Therapeutics Receives Approval from Germany's BfArM to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic CancerUnusual Whales·Jun 25 at 01:21 PMSLXN+15.00%
Silexion Therapeutics Receives Approval from Germany's BfArM to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer | SLXN Stock NewsStockTitan·Jun 22 at 11:40 PMSLXN+15.00%
Silexion Therapeutics presentation highlights SIL204 siRNA program targeting KRAS-driven pancreatic cancerPUBT·Jun 22 at 07:38 AMSLXN+15.00%
Silexion Therapeutics to Attend BIO International Convention 2026 | SLXN Stock NewsStockTitan·Jun 16 at 07:30 AMSLXN+15.00%
Silexion Therapeutics Announces 1-for-10 Reverse Share SplitUnusual Whales·Jun 4 at 06:57 PMSLXN+15.00%
Silexion Therapeutics shares are trading lower after the company announced a 1-for-10 reverse share split.benzinga_article·May 26 at 08:03 AMSLXN+15.00%IBB+0.76%
SLXN On Track, IMVT Hits New High, CTEV Eyes Blockbuster Revenue, Big Day Ahead For BDTXrttnews·May 20 at 09:20 PMHCWB+22.09%SLXN+15.00%
12 Health Care Stocks Moving In Wednesday's Intraday Sessionbenzinga_article·May 20 at 12:05 PMSLXN+15.00%HCWB+22.09%
Nasdaq Gains 100 Points; Target Earnings Top Viewsbenzinga_article·May 20 at 08:46 AM.IXIC+2.78%TGT-0.95%
Silexion Therapeutics Announces Warrant Inducement Financing AgreementTip Ranks·May 15 at 05:44 PMSLXN+15.00%IHE-1.00%
